Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (AURA) is a clinical-stage biotechnology company pioneering precision therapies that target solid tumors while preserving critical organ function. This page serves as the definitive source for investors and medical professionals tracking the company's progress in ocular oncology and bladder cancer treatments.
Access real-time updates on clinical trial developments, regulatory milestones, and strategic partnerships. Our curated news collection includes press releases covering drug candidate advancements (including lead program bel-sar), financial disclosures, and scientific presentations—all essential for evaluating AURA's position in targeted cancer therapeutics.
Key content categories include clinical trial phase updates, FDA designation announcements, collaborative research initiatives, and financial performance reports. The company's innovative molecular surgery approach—combining direct tumor targeting with immune activation—is reflected across all coverage.
Bookmark this page for streamlined monitoring of AURA's progress in vision-preserving ocular melanoma treatments and organ-sparing bladder cancer therapies. Check regularly for authoritative updates on this clinical-stage innovator's journey through the drug development pipeline.
Aura Biosciences (NASDAQ: AURA) has announced the pricing of a public offering expected to raise $75.0 million in gross proceeds. The offering consists of:
- 11,735,565 shares of common stock with warrants to purchase 2,933,891 additional shares
- Pre-funded warrants to purchase 3,571,435 shares (exercise price: $0.00001) with warrants to purchase 892,858 additional shares
The combined offering price is $4.90 per share of common stock and accompanying warrant, while pre-funded warrants are priced at $4.89999. The accompanying warrants have a 5-year term with a $4.90 exercise price. Proceeds will fund clinical programs in early-stage choroidal melanoma, metastases to the choroid, ocular surface cancers, and non-muscle invasive bladder cancer.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on precision therapies for solid tumors, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, warrants to purchase common stock, and pre-funded warrants with accompanying common stock warrants.
The offering will be managed by Leerink Partners and Evercore ISI as joint bookrunning managers, with LifeSci Capital as an additional bookrunning manager. Citizens Capital Markets and Scotiabank are serving as co-managers. The offering will be conducted under a shelf registration statement that was declared effective by the SEC on April 5, 2024.
Aura Biosciences (NASDAQ: AURA) reported Q1 2025 financial results and key developments. The company's lead candidate bel-sar is advancing in multiple clinical trials. The global Phase 3 CoMpass trial for early-stage choroidal melanoma has registered over 220 patients for pre-screening, with potential enrollment completion by end of 2025. The company also enrolled its first patient in a Phase 1b/2 trial for non-muscle-invasive bladder cancer (NMIBC), with initial data expected by year-end 2025.
Financial highlights include cash position of $128.0 million, expected to fund operations into H2 2026. Q1 2025 saw increased R&D expenses of $23.3 million (vs $17.1M in Q1 2024) and net loss of $27.5 million (vs $19.7M in Q1 2024). The company strengthened its leadership by appointing Tony Gibney as CFO and Business Officer.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in three upcoming investor conferences in May 2025:
- The Citizens Life Sciences Conference - Fireside Chat on May 8, 2025, at 9:30 a.m. ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - Fireside Chat on May 20, 2025, at 2:00 p.m. ET
- TD Cowen 6th Annual Oncology Innovation Summit - Fireside Chat on May 27, 2025, at 10:00 a.m. ET
Live webcasts will be available on the company's investor relations website, with replays accessible for 90 days after each presentation.
Aura Biosciences (NASDAQ: AURA) has appointed Teresa Bitetti to its Board of Directors, effective March 31, 2025. Bitetti currently serves as President of the Global Oncology Business Unit at Takeda, where she manages a multi-billion-dollar oncology portfolio across major markets including the US, Europe, and Japan.
As a seasoned executive, Bitetti brings extensive operational and commercial experience from her previous roles, including Senior Vice President positions at Bristol Myers Squibb (BMS) where she led worldwide oncology commercialization and headed U.S. Oncology operations. Her expertise spans multiple therapeutic areas including infectious diseases and neuroscience.
The appointment aligns with Aura's focus on developing precision therapies for solid tumors while preserving organ function, particularly in ocular and urologic oncology.
Aura Biosciences (NASDAQ: AURA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company's lead candidate bel-sar showed positive Phase 1 trial data in Non-Muscle Invasive Bladder Cancer (NMIBC) at the European Association of Urology Congress, demonstrating clinical complete responses and robust cell-mediated immunity.
The Phase 3 CoMpass trial for early-stage choroidal melanoma is actively enrolling globally, with over 175 patients registered in pre-screening since June 2024. The company has also initiated a Phase 2 trial for metastases to the choroid, with initial data expected in 2025.
Financial highlights include:
- Cash position of $151.1 million, expected to fund operations into 2H 2026
- R&D expenses increased to $73.3 million for full year 2024
- Net loss of $86.9 million for full year 2024
Aura Biosciences (NASDAQ: AURA) announced positive data from a completed Phase 1 trial of bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients. The trial included 15 patients, evaluating safety and feasibility of local bel-sar administration.
Key findings:
- In patients receiving bel-sar with light activation (n=10), 4 out of 5 intermediate-risk patients showed complete clinical response
- In high-risk patients, 1 out of 5 demonstrated complete response, with 3 showing tumor shrinkage
- 57% of patients with multiple tumors showed complete response in non-target tumors
- Safety profile was favorable with only Grade 1 drug-related events in less than 10% of patients
- Significant immune response observed with infiltration of effector cells and formation of tertiary lymphoid structures
The treatment demonstrated potential as a front-line focal treatment approach for NMIBC patients, with administration possible without general anesthesia.
Aura Biosciences (NASDAQ: AURA) has announced that additional Phase 1 data for bel-sar (AU-011) in treating non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology Congress in Madrid, Spain (March 21-24, 2025).
The late-breaking presentation by Dr. Seth Lerner will focus on the safety and efficacy of Bel-sar, a Virus-like-Drug-Conjugate (VDC). Additionally, a Research Forum will discuss VDCs as a paradigm-shifting approach for bladder cancer treatment.
The ongoing Phase 1 trial is designed as a window of opportunity study evaluating bel-sar as a monotherapy before standard TURBT procedure. The study aims to assess local administration approaches and includes histopathological evaluation after a single dose to examine biological activity and immune response.
Aura will host a virtual urologic oncology investor event on March 24, 2025, featuring key opinion leaders to discuss the trial data and future development plans, including the planned Phase 1b/2 trial expansion.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors, has announced its participation in two upcoming investor conferences in March 2025.
CEO Elisabet de los Pinos will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 9:10 a.m. ET. She will also attend the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, with a fireside chat scheduled for 8:00 a.m. ET.
Live webcasts of both presentations will be available on the "Investors & Media" page under the "Events & Presentations" section of Aura's website. Replays will remain accessible for 90 days following each presentation.
Aura Biosciences (NASDAQ: AURA) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. CEO Elisabet de los Pinos will engage in a fireside chat on December 3, 2024, at 2:35 p.m. ET. The clinical-stage biotechnology company, which focuses on developing precision therapies for solid tumors, will make the presentation available via live webcast on their investor relations website. A replay will be accessible for 90 days after the event.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
